PT-141 (10 mg) + Melanotan II (10 mg) Stack Dosage Protocol

PT-141 & Melanotan II (10 mg Vials) Dosage Protocol

PT-141 (10 mg) + Melanotan II (10 mg) Stack peptide vial

Quickstart Highlights

PT-141 (bremelanotide) and Melanotan II are cyclic melanocortin receptor agonists with distinct but related applications. PT-141 is FDA-approved for hypoactive sexual desire disorder and is used on-demand[1][2], while Melanotan II has been studied for its effects on skin pigmentation and sexual function with daily dosing protocols[5][6]. This educational guide covers reconstitution, dosing, and administration for both peptides.

  • Reconstitute each: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • PT-141 dose: 750–1750 mcg on-demand (≥45 min before activity); max 1 dose per 24 h.
  • Melanotan II dose: 250–1000 mcg once daily with gradual titration.
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F) and use within ~1 week.

Dosing & Reconstitution Guide

Educational guide for reconstitution and dosing of both peptides

PT-141 (Bremelanotide) — On-Demand Protocol (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection (abdomen or thigh). Frequency: On-demand, at least 45 minutes before anticipated sexual activity; no more than 1 dose per 24 hours and ≤8 doses per month[1][3].

Phase Dose (mcg) Units (per injection) (mL)
Initial / Titration 500–750 mcg 15–22 units (0.15–0.22 mL)
Standard 1000–1500 mcg 30–45 units (0.30–0.45 mL)
Full / FDA-Approved 1750 mcg (1.75 mg) 52 units (0.52 mL)

Titration: Start at a lower dose (500–750 mcg) and increase as tolerated. Nausea is common with initial use and typically diminishes with subsequent doses[2][4].

Melanotan II — Daily Protocol (3 mL = ~3.33 mg/mL)

Route: Subcutaneous injection (abdomen or thigh). Frequency: Once daily during loading phase; reduced frequency for maintenance[5][6].

Week Daily Dose (mcg) Units (per injection) (mL)
Week 1 250 mcg 7.5 units (0.075 mL)*
Week 2 500 mcg 15 units (0.15 mL)
Weeks 3–4 750 mcg 22 units (0.22 mL)
Weeks 5+ (Loading) 1000 mcg 30 units (0.30 mL)
Maintenance 500–1000 mcg (2–3×/week) 15–30 units (0.15–0.30 mL)

*For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Titration: Begin at 250 mcg and increase by 250 mcg every 5–7 days as tolerated. Nausea and flushing are common initially and typically subside with continued use[6].

Reconstitution Steps (Both Peptides)

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming or direct impact on the powder.
  3. Gently swirl or roll until fully dissolved (do not shake).
  4. Label with date, peptide name, and concentration; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  5. Use reconstituted solution within approximately 1 week for optimal stability[7].

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week protocol. PT-141 assumes ~1 dose/week on-demand; Melanotan II assumes daily loading then maintenance.

PT-141 (On-Demand, ~1×/week)

  • Peptide Vials (PT-141, 10 mg each):

    • 8 weeks: 2 vials
    • 12 weeks: 3 vials
    • 16 weeks: 4 vials
  • Insulin Syringes (U-100):

    • 8 weeks: 8 syringes
    • 12 weeks: 12 syringes
    • 16 weeks: 16 syringes
  • Bacteriostatic Water (10 mL bottles):

    • 8 weeks (2 vials × 3 mL): 1 bottle
    • 12 weeks (3 vials × 3 mL): 1 bottle
    • 16 weeks (4 vials × 3 mL): 2 bottles

Melanotan II (Daily Loading → Maintenance)

  • Peptide Vials (Melanotan II, 10 mg each):

    • 8 weeks: 6 vials
    • 12 weeks: 9 vials
    • 16 weeks: 12 vials
  • Insulin Syringes (U-100):

    • 8 weeks: 56 syringes (7/day × 8 weeks)
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles):

    • 8 weeks (6 vials × 3 mL = 18 mL): 2 bottles
    • 12 weeks (9 vials × 3 mL = 27 mL): 3 bottles
    • 16 weeks (12 vials × 3 mL = 36 mL): 4 bottles

Shared Supplies

  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration.

    • 8 weeks: 128 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 192 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 256 swabs → recommend 3 × 100-count boxes
PT-141 10 mg Vial
View Supplier
Melanotan II 10 mg Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Summary of both peptide regimens.

  • PT-141: On-demand subcutaneous use for sexual function; typical dose 1.75 mg (1750 mcg) administered ≥45 min before activity[1].
  • Melanotan II: Daily subcutaneous injections during loading phase (4–8 weeks), then 2–3× weekly maintenance for pigmentation and related effects[5].
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for both peptides.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Dosing Protocols

Key differences between the two peptides.

  • PT-141: Start at 500–750 mcg; titrate to 1750 mcg as tolerated. On-demand use only; max 8 doses/month[2].
  • Melanotan II: Start at 250 mcg daily; increase by 250 mcg every 5–7 days to target 1000 mcg. Transition to maintenance after desired effect[6].
  • Timing: PT-141 at least 45 min before activity; Melanotan II at any consistent time daily.
  • Sites: Rotate injection sites (abdomen, thighs) for both.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; PT-141 shows short-term room-temperature stability (~3 weeks) if needed[7].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 1 week for optimal potency.
  • Avoid repeated freeze–thaw cycles; allow vials to reach room temperature before opening to reduce condensation.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each injection; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document each dose, time, and injection site to maintain consistency.
  • PT-141: Do not exceed 8 doses per month or 1 dose per 24 hours[1].
  • Melanotan II: UV exposure (sun or controlled tanning) during use may enhance pigmentation effects; appropriate sun protection is advised[6].

How These Peptides Work

PT-141 and Melanotan II are both synthetic cyclic peptide analogues that act on melanocortin receptors, particularly MC3R and MC4R in the central nervous system[2][5]. PT-141 (bremelanotide) is a metabolite of Melanotan II and was developed specifically for its effects on sexual function without significant pigmentation activity. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women[1][3]. Melanotan II retains both melanogenic and sexual-function properties, stimulating melanin production in skin cells (melanocytes) while also activating central pathways involved in sexual arousal[5][6].

Potential Benefits & Side Effects

Observations from clinical and research literature.

PT-141

  • Shown to increase sexual desire and reduce distress associated with low libido in clinical trials[2][3].
  • Common side effects include nausea (especially with first doses), flushing, headache, and injection-site reactions[4].
  • May cause transient increases in blood pressure; use with caution in those with cardiovascular conditions[1].

Melanotan II

  • Studied for inducing skin pigmentation (tanning) without UV exposure and for effects on erectile function[5][6].
  • Common side effects include nausea, facial flushing, fatigue, and appetite suppression, particularly during initial dosing[6].
  • May cause darkening of existing moles or nevi; monitoring is advised.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Maintain adequate hydration, especially given potential nausea with initial doses.
  • For Melanotan II users seeking pigmentation: controlled, gradual UV exposure may enhance results; always use appropriate sun protection to minimize skin damage risk.
  • Prioritize sleep and stress management; both influence hormonal balance and overall response.
  • Monitor for any new or changing skin lesions and consult a healthcare provider if noted.

Injection Technique

General subcutaneous guidance from clinical best-practice resources[8][9].

  • Clean the vial stopper with an alcohol swab; allow to dry completely.
  • Clean the injection site (abdomen or thigh) with an alcohol swab for at least 30 seconds; allow to dry[8].
  • Pinch a fold of skin; insert the needle at 45–90° depending on subcutaneous tissue depth[9][10].
  • Aspiration is not required for subcutaneous injections; inject slowly and steadily[8].
  • Release the skin fold, withdraw the needle, and apply gentle pressure if needed.
  • Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy or irritation[9].

Important Note

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • FDA
    — Bremelanotide (Vyleesi) prescribing information: dosing, safety, and use limitations
    View Source

  • NCBI Bookshelf (LiverTox)
    — Bremelanotide: mechanism, clinical use, and hepatic safety profile
    View Source

  • PMC
    — Bremelanotide for treatment of female hypoactive sexual desire disorder: clinical trial review
    View Source

  • Mayo Clinic
    — Bremelanotide (subcutaneous route): side effects, dosage, and precautions
    View Source

  • PubMed
    — Evaluation of Melanotan-II: pilot phase-I clinical study on safety and efficacy
    View Source

  • RxList
    — Melanotan-II: uses, side effects, dosing, and precautions overview
    View Source

  • Bachem
    — Handling and storage guidelines for peptides: lyophilized and reconstituted stability
    View Source

  • NCBI Bookshelf (WHO)
    — Best practices for injections and related procedures: asepsis and technique
    View Source

  • Healthline
    — Subcutaneous injection: technique, sites, and step-by-step guidance
    View Source

  • CDC
    — Vaccine administration: subcutaneous injection angle and site selection
    View Source

  • PMC
    — Subcutaneous drug injection: pharmacologic considerations and clinical review
    View Source

  • Pure Lab Peptides
    — PT-141 (10 mg) product page: quality and batch documentation
    View Source

  • Pure Lab Peptides
    — Melanotan II (10 mg) product page: quality and batch documentation
    View Source